Advertisement


Andrew James Martin, PhD, on Oral Nicotinamide for Nonmelanoma Skin Cancer

2015 ASCO Annual Meeting

Advertisement

Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, discusses a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-risk patients (Abstract 9000).



Related Videos

Hematologic Malignancies

Ruben A. Mesa, MD, Summarizes Results of the PERSIST-1 Study on Myelofibrosis

Ruben A. Mesa, MD, of the Mayo Clinic, discusses pacritinib and its significant efficacy in myelofibrosis (

CNS Cancers

Jan C. Buckner, MD, on Whole-Brain Radiation and Radiosurgery in Patients With Brain Metastases

Jan C. Buckner, MD, of the Mayo Clinic discusses adjuvant whole-brain radiotherapy and the need for initial treatment with radiosurgery and close monitoring to preserve cognitive f...

Lung Cancer

Luis G. Paz-Ares, MD, PhD, Summarizes Results of the CheckMate 057 Trial on Nonsquamous Cell NSCLC

Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario Doce De Octubre, discusses the superior overall survival in patients taking nivolumab vs docetaxel in advanced nonsquamous ...

Breast Cancer

Maura N. Dickler, MD, and Clifford A. Hudis, MD, on Results From the CALGB Alliance Trial on Hormone Receptor–Positive Advanced Breast Cancer

Clifford A. Hudis, MD, and Maura N. Dickler, MD, of Memorial Sloan Kettering Cancer Center, discuss adding bevacizumab to letrozole as a first-line endocrine thera...

Breast Cancer

Jame Abraham, MD, Summarizes Results From the NeoSphere and ExteNET Trials for Breast Cancer

Jame Abraham, MD, of the Cleveland Clinic discusses analyses of two trials for locally advanced, inflammatory, or early HER2-positive breast cancer using docetaxel, trastuzumab, pe...

Advertisement

Advertisement



;
Advertisement